Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics adds former Incyte executive Vijay Iyengar to board

Neutral Impact 2 of 5 leadership Written later

Whitehawk Therapeutics increased its board from nine to ten directors and appointed Vijay Iyengar, M.D., as a Class III director effective September 9, 2026. Dr. Iyengar previously served as Executive Vice President at Incyte Corporation until November 2025, and the filing describes his oncology and life sciences experience as the basis for his appointment.

Key points

  • Board size increased from nine to ten; Dr. Iyengar's term expires at the 2029 annual meeting
  • Non-employee director base annual retainer of $40,000 under the Outside Director Compensation Policy
  • Initial stock option grant of 76,080 shares, vesting monthly over three years
  • Served as Executive Vice President at Incyte Corporation from May 2022 to November 2025

The filing

CompanyWhitehawk Therapeutics, Inc. (WHWK)
Form8-K, current report
Filed with the SECSep 10, 2026, 5:02 PM ET
Accession number0001193125-26-388010

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.